BioCryst Pharmaceuticals announced that the Italian Medicines Agency, Agenzia Italiana del Farmaco, has finalized reimbursement and recommended ORLADEYO for the routine prevention of recurrent attacks of hereditary angioedema in eligible patients 12 years and older. With this recommendation, HAE patients in Italy now have access to the first oral, once-daily therapy for the routine prevention of recurrent HAE attacks. The AIFA decision follows European Commission marketing authorization of ORLADEYO in April 2021.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BCRX:
- BioCryst Launches ORLADEYO® (berotralstat) in Italy
- BioCryst to Report Fourth Quarter 2023 Financial Results on February 26
- BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BioCryst reports inducement grants under Nasdaq listing rule
